UPDATE: PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for patient enrollment in Phase III Breast Cancer Trial
HAYWARD, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, is pleased to announce the publication of a landmark study in The New England Journal of Medicine (NEJM), demonstrating the clinical utility of the …